Absci Corporation (Nasdaq: ABSI), a leader in generative AI
antibody discovery, today announced a collaboration with
AstraZeneca, a global biopharmaceutical company, to deliver an
AI-designed antibody against an oncology target. This collaboration
combines Absci's Integrated Drug Creation™ platform with
AstraZeneca's expertise in oncology with the goal of accelerating
the discovery of a potential new cancer treatment candidate.
Absci will contribute its pioneering generative AI technology to
deliver a therapeutic candidate antibody for a specified oncology
target. The agreement includes an upfront commitment, R&D
funding and milestone payments, in addition to royalties on product
sales.
“AstraZeneca is a leader in developing novel treatments in
oncology, and we are excited to collaborate with them to design a
therapeutic candidate antibody with the potential to improve the
lives of cancer patients,” said Sean McClain, Absci Founder &
CEO. “This agreement advances Absci’s goal of creating a new
generation of life-changing and transformative therapeutics using
its AI platform.”
Absci’s Integrated Drug Creation™ platform harnesses generative
AI and a suite of scalable wet-lab technologies. The platform
generates proprietary data by measuring millions of protein-protein
interactions. These data are used to train Absci’s proprietary AI
models and, in later iterations, to validate antibodies designed
using the de novo AI models. The platform accelerates drug
discovery by completing the cycle of data collection, AI-driven
design, and wet-lab validation within an estimated six weeks. It
aims to enhance the likelihood of successful development outcomes
for biologic drug candidates by optimizing multiple drug attributes
concurrently and expanding the universe of drug targets to include
those previously deemed “undruggable” such as GPCRs and ion
channels.
Puja Sapra, Ph.D., Senior Vice President of Biologics
Engineering & Oncology Targeted Delivery, AstraZeneca said,
"This collaboration is an exciting opportunity to utilize Absci's
de novo AI antibody creation platform to design a potential new
antibody therapy in oncology."
Today’s agreement comes on the heels of Absci’s publication on
the design and validation of de novo antibodies using Absci’s
state-of-the-art 'zero-shot' generative AI model and follows
additional collaborations with leading biopharmaceutical,
healthcare and technology organizations.
About Absci
Absci is a generative AI drug creation company that combines AI
with scalable wet lab technologies to create better biologics for
patients, faster. Our Integrated Drug Creation™ platform unlocks
the potential to accelerate time to clinic and increase the
probability of success by simultaneously optimizing multiple drug
characteristics important to both development and therapeutic
benefit. With the data to learn, the AI to create, and the wet lab
to validate, Absci can screen billions of cells per week, allowing
it to go from AI-designed antibodies to wet lab-validated
candidates in as little as six weeks. Absci’s vision is to deliver
breakthrough therapeutics at the click of a button, for everyone.
Absci's headquarters is in Vancouver, WA, its AI Research Lab is in
New York City, and its Innovation Center is in Zug, Switzerland.
Visit www.absci.com and follow us on LinkedIn (@absci), X (Twitter)
(@Abscibio), and YouTube.
Availability of Other Information about AbsciInvestors and
others should note that we routinely communicate with investors and
the public using our website (www.absci.com) and our investor
relations website (investors.absci.com), including without
limitation, through the posting of investor presentations, SEC
filings, press releases, public conference calls and webcasts on
these websites, as well as on X (Twitter), LinkedIn and YouTube.
The information that we post on these websites and social media
outlets could be deemed to be material information. As a result,
investors, the media, and others interested in Absci are encouraged
to review this information on a regular basis. The contents of our
website and social media postings, or any other website that may be
accessed from our website or social media postings, shall not be
deemed incorporated by reference in any filing under the Securities
Act of 1933, as amended.
Absci Forward-Looking StatementsCertain statements in this press
release that are not historical facts are considered
forward-looking within the meaning of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended, including statements containing the words
“will,” “may,” “pursues,” “anticipates,” “plans,” “believes,”
“aims,” “potential,” “forecast,” “estimates,” “extends,” “expects,”
and “intends,” or similar expressions. We intend these
forward-looking statements, including statements regarding the
potential benefits of our technology development efforts and the
application of those efforts, including acceleration of drug
development timelines, reducing the time and costs related to drug
development, advancements toward drug discovery and development
activities, the potential benefits of our collaboration with
AstraZeneca, potential milestone and royalty payments due under our
agreement with AstraZeneca, and the effective incorporation of our
technology in drug design, research and technology development
collaboration efforts, to be covered by the safe harbor provisions
for forward-looking statements contained in Section 27A of the
Securities Act and Section 21E of the Securities Exchange Act, and
we make this statement for purposes of complying with those safe
harbor provisions. These forward-looking statements reflect our
current views about our plans, intentions, expectations,
strategies, and prospects, which are based on the information
currently available to us and on assumptions we have made. We can
give no assurance that the plans, intentions, expectations, or
strategies will be attained or achieved, and furthermore, actual
results may differ materially from those described in the
forward-looking statements and will be affected by a variety of
risks and factors that are beyond our control, including, without
limitation, risks and uncertainties relating to our ability to
effectively collaborate on research, drug discovery and development
activities with our partners or potential partners and challenges
inherent in the discovery and development of therapeutic assets;
along with those risks set forth in our most recent periodic report
filed with the U.S. Securities and Exchange Commission, as well as
discussions of potential risks, uncertainties, and other important
factors in our subsequent filings with the U.S. Securities and
Exchange Commission. Except as required by law, we assume no
obligation to update publicly any forward-looking statements,
whether as a result of new information, future events, or
otherwise.
Absci Investor ContactAlex Khan, VP, Finance & Investor
Relationsinvestors@absci.com
Absci Media Contactpress@absci.com
AbSci (NASDAQ:ABSI)
過去 株価チャート
から 4 2024 まで 5 2024
AbSci (NASDAQ:ABSI)
過去 株価チャート
から 5 2023 まで 5 2024